<DOC>
	<DOCNO>NCT00004400</DOCNO>
	<brief_summary>OBJECTIVES : I . Determine whether physiologic testosterone replacement increase fat-free mass , therefore contribute weight maintenance , improved muscle function , quality life HIV-infected woman . II . Examine mechanism testosterone-induced increase fat-free mass .</brief_summary>
	<brief_title>Phase II Randomized Study Physiologic Testosterone Replacement Premenopausal , HIV-Positive Women</brief_title>
	<detailed_description>PROTOCOL OUTLINE : This randomize , double blind , placebo control study . Patients randomize one three arm . Arm I : Patients receive two placebo transdermal patch apply twice week ( every 3-4 day ) . Arm II : Patients receive one testosterone transdermal patch one placebo transdermal patch apply twice week ( every 3-4 day ) . Arm III : Patients receive two testosterone transdermal patch apply twice week ( every 3-4 day ) . Patients receive 12 week treatment absence adverse reaction health deterioration . Patients follow day 1 , every 2 week treatment , end recovery period . Quality life assess treatment begin week 6 12 . Completion date provide represent completion date grant per OOPD record</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Cachexia</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Histologically confirm premenopausal HIVpositive woman experience 515 % weight loss Prior/Concurrent Therapy Endocrine therapy : At least 3 month since megestrol At least 3 month since anabolic androgenic steroid At least 3 month since oral contraceptive At least 3 month since DepoProvera No concurrent hormone replacement therapy Other : Concurrent retroviral protease inhibitor allow , dosage must stable At least 3 month since ketoconazole At least 6 week since initiation protease inhibitor Patient Characteristics Hepatic : No significant liver disease SGOT/SGPT great 3 time upper limit normal ( ULN ) Alkaline phosphatase great 3 time ULN Bilirubin great 2 mg/dL No medical complication due alcohol abuse Renal : Not specify Cardiovascular : No significant cardiovascular disease No uncontrolled hypertension Other : Testosterone level ( early morning ) less 30 ng/dL Normal gastrointestinal function indicate : Absence diarrhea Normal Dxylose absorption test No acute opportunistic infection infectious illness No malignant disease No history breast cancer No history endometrial cancer No fever know unknown origin No unremitting diarrhea define : At least 4 watery stool per day OR More 4 watery stool recently OR Acute change stool habit fever No significant respiratory disease No diabetes No illicit drug within past 6 month No history hyperandrogenic disorder : Hirsutism Polycystic ovary disease Not pregnant lactating</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 1998</verification_date>
	<keyword>cachexia</keyword>
	<keyword>disease-related problem/condition</keyword>
	<keyword>human immunodeficiency virus infection</keyword>
	<keyword>immunologic disorder infectious disorder</keyword>
	<keyword>nutrition</keyword>
	<keyword>quality life</keyword>
	<keyword>rare disease</keyword>
	<keyword>viral infection</keyword>
</DOC>